Hide filtersShow filters × Close Bryan, Garnier & Co successfully advises AS INFOR’s shareholders on the sale of the company to CEGID Group Bryan, Garnier & Co leads €45 million secondary placement of Parrot shares on Euronext Bryan, Garnier & Co successfully advised Influe shareholders in their merger with Generix Bryan, Garnier & Co successfully leads a €66.1 million capital increase for Sword Group Bryan Garnier & Co leads €15 million IPO of the first internet up-market wines retailer on Alternext, Euronext’s alternative investment market Bryan, Garnier & Co successfully leads a €33.7 million IPO for Innate Pharma Bryan Garnier & Co successfully leads a EUR 19.1 million follow-on offering for Risc Group (Euronext: RSC) Bryan Garnier & Co successfully leads a EUR 3.8 million follow-on offering for Access Commerce (Euronext: CES), the leading Multi-channel Commerce solutions company Bryan, Garnier & Co successfully advised Divalto on the opening of its capital to Before, through an owner buy-out (OBO) Bryan, Garnier & Co leads a 11,5 million IPO for MEDICREA on Alternext Bryan, Garnier & Co & ING announce the successful completion of BioAlliance Pharma (Eurolist Paris : FR0010095596) EUR 30 m Initial Public Offering Bryan, Garnier & Co, the European Growth Investment Bank, announces today the successful closing of a Eur 49 million secondary placement of 21 Centrale Partners’ 27.5% stake in SWORD (Euronext: SWP)
